What is all about?

The Global Liver Health Forum objective is to enhance knowledge on the identification and intervention strategies employed in the management of MASLD/MAFLD and the identification of the associated metabolic risks, it gathers experts across the globe to bring the latest perspectives on this important topic.

Evolving horizons in MASLD

Integrating lifestyle, pharmacology, and patient-centered outcomes

Optimizing MASLD management

current strategies combining lifestyle and pharmacological options

Metabolic risk burden in MASLD

Key findings on EXCEL study results

 Beyond the liver

Understanding the holistic impact of MASLD on patient Quality of Life

Our experts

 Prof. Dr. Münevver Demir is a distinguished clinician-scientist specializing in hepatology and gastroenterology. With robust training from Mainz and Cologne and clinical leadership...

Obtained his Medical degreefrom the Faculty of Medicine,
Cairo University in Egypt. He pursued his postgraduate
studies and activities in internal medicine in the UK...

Prof. Norbert Stefan is a globally recognized clinician-scientist based at the University of Tübingen & Helmholtz Zentrum München. His major contributions lie in human metabolic...

Obtained his medical degree from the Medical University of Silesia in Katowice, Poland, in 1986, before pursuing a specialization in internal medicine...

Find out more about the previous global liver health forums at
www.globalliverforum.com/en/past-summits
or scan the qr code

Global Liver Forum link adress QR code

Resources for you and your patients

What would be the best therapeutic approach of EPLs as adjunctive treatment for MASLD on top of Standard of Care?

Gastroenterologist

Professor Marek Hartleb

What outcomes matter beyond fatty liver and how MASLD can affect and deteriorate patients' QoL?

Gastroenterologist

Professor Marek Hartleb

How EPLs can perform on top of Standard of Care in QoL relief?

Professor Marek Hartleb

Gastroenterologist

What is you position about EPLs as potential adjunctive treatment for T2DM patients with MASLD?

Gastroenterologist

Professor Marek Hartleb

Could you detail more about CLDQ-MASLD/MASH test and the relevance of it to assess QoL improvements in your patients?

Gastroenterologist

Professor Marek Hartleb

What is metabolic fatty liver? How might our consumers understand it better?

Patient

Professor Marek Hartleb

What are the common risk factors of fatty liver (MASLD)?

Patient

Professor Marek Hartleb

Can you deszcribe the progression of fatty liver (MASLD) if left untreated?

Patient

Professor Marek Hartleb

When does a patient need to be worried about getting themselves checked for fatty liver (MASLD)?

Patient

Professor Marek Hartleb

Is fatty liver (MASLD) reversible?

Patient

Professor Marek Hartleb

What would be the best therapeutic approach of EPLs as adjunctive treatment for MASLD on top of Standard of Care?

Gastroenterologist

Professor Assad Dajani

What outcomes matter beyond fatty liver and how MASLD can affect and deteriorate patients' QoL?

Gastroenterologist

Professor Assad Dajani

How EPLs can perform on top of Standard of Care in QoL relief?

Gastroenterologist

Professor Assad Dajani

What is you position about EPLs as potential adjunctive treatment for T2DM patients with MASLD?

Gastroenterologist

Professor Assad Dajani

Could you detail more about CLDQ-MASLD/MASH test and the relevance of it to assess QoL improvements in your patients?

Gastroenterologist

Professor Assad Dajani

What is metabolic fatty liver? How might our consumers understand it better?

Patient

Professor Assad Dajani

What are the common risk factors of fatty liver (MASLD)?

Patient

Professor Assad Dajani

Can you deszcribe the progression of fatty liver (MASLD) if left untreated?

Patient

Professor Assad Dajani

When does a patient need to be worried about getting themselves checked for fatty liver (MASLD)?

Patient

Professor Assad Dajani

Is fatty liver (MASLD) reversible?

Patient

Professor Assad Dajani

What would be the best therapeutic approach of EPLs as adjunctive treatment for MASLD on top of Standard of Care?

Gastroenterologist

Professor Norbert Stefan

What outcomes matter beyond fatty liver and how MASLD can affect and deteriorate patients' QoL?

Gastroenterologist

Professor Norbert Stefan

How EPLs can perform on top of Standard of Care in QoL relief?

Gastroenterologist

Professor Norbert Stefan

What is you position about EPLs as potential adjunctive treatment for T2DM patients with MASLD?

Gastroenterologist

Professor Norbert Stefan

Could you detail more about CLDQ-MASLD/MASH test and the relevance of it to assess QoL improvements in your patients?

Gastroenterologist

Professor Norbert Stefan

What is metabolic fatty liver? How might our consumers understand it better?

Patient

Professor Norbert Stefan

What are the common risk factors of fatty liver (MASLD)?

Patient

Professor Norbert Stefan

Can you deszcribe the progression of fatty liver (MASLD) if left untreated?

Patient

Professor Norbert Stefan

When does a patient need to be worried about getting themselves checked for fatty liver (MASLD)?

Patient

Professor Norbert Stefan

Is fatty liver (MASLD) reversible?

Patient

Professor Norbert Stefan

See all resources